ATE226449T1 - Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen - Google Patents

Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen

Info

Publication number
ATE226449T1
ATE226449T1 AT99964038T AT99964038T ATE226449T1 AT E226449 T1 ATE226449 T1 AT E226449T1 AT 99964038 T AT99964038 T AT 99964038T AT 99964038 T AT99964038 T AT 99964038T AT E226449 T1 ATE226449 T1 AT E226449T1
Authority
AT
Austria
Prior art keywords
pharmaceutical preparations
associated virus
excipients
compositions
produced therefrom
Prior art date
Application number
AT99964038T
Other languages
German (de)
English (en)
Inventor
Hema S Sista
Yero J Espinoza
Original Assignee
Avigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avigen Inc filed Critical Avigen Inc
Application granted granted Critical
Publication of ATE226449T1 publication Critical patent/ATE226449T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT99964038T 1998-12-03 1999-12-02 Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen ATE226449T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11068998P 1998-12-03 1998-12-03
PCT/US1999/028460 WO2000032233A2 (en) 1998-12-03 1999-12-02 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith

Publications (1)

Publication Number Publication Date
ATE226449T1 true ATE226449T1 (de) 2002-11-15

Family

ID=22334360

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99964038T ATE226449T1 (de) 1998-12-03 1999-12-02 Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen

Country Status (9)

Country Link
EP (1) EP1144009B1 (https=)
JP (5) JP2002531418A (https=)
AT (1) ATE226449T1 (https=)
AU (2) AU773834B2 (https=)
CA (1) CA2353417C (https=)
DE (1) DE69903666T2 (https=)
ES (1) ES2185417T3 (https=)
PT (1) PT1144009E (https=)
WO (1) WO2000032233A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080977A1 (en) * 2001-04-04 2002-10-17 Delsitech Oy Biodegradable carrier and method for preparation thereof
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
LT2816118T (lt) 2005-05-31 2018-12-10 The Regents Of The University Of Colorado, A Body Corporate Genų pristatymo būdai
CA2742817A1 (en) * 2008-11-20 2010-05-27 Biogen Idec Ma Inc. Arginine inactivation of viruses
JP6348064B2 (ja) 2011-11-22 2018-06-27 ザ チルドレンズ ホスピタル オブ フィラデルフィア 効率の高いトランスジーン送達のためのウイルスベクター
EP3436078B1 (en) 2016-03-31 2021-10-27 University of Cincinnati Methods and compositions for the treatment of als
JP2019530737A (ja) 2016-08-23 2019-10-24 アコーオス インコーポレイテッド ヒト対象において非加齢性聴力障害を治療するための組成物および方法
EP3626821A4 (en) 2017-05-18 2021-03-03 Kyoto University COMPOSITION FOR THE PREVENTION OR TREATMENT OF SPINOCEREBEL ATAXIA TYPE 36
EP3720500A4 (en) * 2017-12-05 2021-08-25 Applied Genetic Technologies Corporation FORMULATION OPTIMIZATION FOR VIRAL PARTICLES
US20220143115A1 (en) * 2019-04-19 2022-05-12 Regenxbio Inc. Adeno-Associated Virus Vector Formulations and Methods
US20220325250A1 (en) 2019-08-14 2022-10-13 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
JP7807380B2 (ja) 2020-02-21 2026-01-27 アコーオス インコーポレイテッド ヒト対象において非加齢関連聴力障害を処置するための組成物および方法
US20240066146A1 (en) * 2020-12-18 2024-02-29 Sangamo Therapeutics, Inc. Improved pharmaceutical compositions containing adeno-associated viral vector

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US6521225B1 (en) * 1996-09-06 2003-02-18 Chiron Corporation AAV vectors

Also Published As

Publication number Publication date
JP2016040330A (ja) 2016-03-24
AU2004205308A1 (en) 2004-09-23
AU2036100A (en) 2000-06-19
JP2002531418A (ja) 2002-09-24
DE69903666D1 (de) 2002-11-28
CA2353417C (en) 2008-04-22
JP2014058578A (ja) 2014-04-03
WO2000032233A2 (en) 2000-06-08
EP1144009B1 (en) 2002-10-23
DE69903666T2 (de) 2003-07-03
JP5663285B2 (ja) 2015-02-04
AU773834B2 (en) 2004-06-10
EP1144009A2 (en) 2001-10-17
PT1144009E (pt) 2003-01-31
JP2011046748A (ja) 2011-03-10
JP2017206556A (ja) 2017-11-24
ES2185417T3 (es) 2003-04-16
WO2000032233A3 (en) 2001-10-18
CA2353417A1 (en) 2000-06-08
EP1144009A3 (en) 2002-02-06

Similar Documents

Publication Publication Date Title
ATE226449T1 (de) Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen
DE69940354D1 (de) Adenovirus-formulierungen zur gentherapie
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
DE60119968D1 (en) Hepatitis c tripeptid inhibitoren
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
FI971613A7 (fi) Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin
ATE353665T1 (de) Glp-2 enthaltende formulierungen
EP0710288A4 (en) ADENOVIRAL VECTORS FOR TREATMENT OF HEMOPHILIA
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
MX9603002A (es) Procedimiento para la preparacion de virus asociados a los adenovirus (aav), recombinantes, y usos de los mismos.
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
NO905438L (no) Virusmiddel.
ATE270342T1 (de) Endosomolytisch wirksame partikel
PT935609E (pt) Composicoes cristalizaveis que contem um complexo entre o dominio de protease ns3 do virus da hepatite c e ns4a cristais resultantes
FR2704556B1 (fr) Virus recombinants et leur utilisation en thérapie génique.
AU2003235764A8 (en) Viruses with enhanced lytic potency
EA200001193A1 (ru) 2-фенил-1-[4-(2-аминоэтокси)бензил]индол в комбинации с эстрогенами
BR9909087A (pt) Formulações para proteção de conjugados peg-alfa interferon
NO983946D0 (no) Parapoksyviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
ATE268181T1 (de) Pharmazeutische zubereitungen enthaltend alginate
ATE303816T1 (de) Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
ATE255594T1 (de) Hepatitis b inhibitoren
RU2006118106A (ru) Вектор химерного аденовируса типа 5/типа 35
DE69728447D1 (de) Veränderte, kleine rna-viren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties